TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11171786
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II type 1 receptor antagonist (losartan 100 mg/d)
Study: 31071249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6 strains of probiotics for 3 months
Study: 27876806
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg aspirin (ASA)
Study: 25972532
Drug: 2 portions
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 portions of FVs daily (160 g)
Study: 25972532
Drug: 4 portions
Normalized name: nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 portions of FVs daily (320 g)
Study: 25972532
Drug: 7 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 portions of FVs daily (560 g)
Study: 11348708
Drug: Hepacare (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepacare (1 month/two dose regimen)
Study: 11348708
Drug: Engerix-B (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (2 month/three dose regimen)
Study: 8424293
Drug: Prophylactic dixyrazine
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dixyrazine 0.25 mg kg‐1 i.v. after surgery
Study: 27141627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medication)
Study: 10198297
Drug: Mixed amino
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amino acid (MAA) solution (40 g)
Study: 10198297
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acid (EAA) solution (40 g)
Study: 7775360
Drug: Methylphenidate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.4 to 1.3 mg/kg per day, mean 0.7 mg/kg per day)
Study: 7775360
Drug: Bupropion (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (1.4 to 5.7 mg/kg per day, mean 3.3 mg/kg per day)
Study: 1692095
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with radiation
Study: 2859523
Drug: Combined radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation and chemotherapy
Study: 498151
Drug: cis-platinum (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-platinum (100 mg/m2) administered via rapid infusion (15-minute)
Study: 498151
Drug: cis-platinum (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-platinum (100 mg/m2) administered via 6-hour infusion
Study: 498151
Drug: cis-platinum with
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-platinum with concomitant administration of mannitol
Study: 31215242
Drug: Classical oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical oral Navelbine (once weekly)
Study: 23648613
Drug: Segmental muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Segmental muscle vibration (SMV) combined with general physical therapy
Study: 23648613
Drug: General physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General physical therapy (Control)
Study: 19957513
Drug: Cognitive impairment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive impairment group (serum uric acid level: 249 micromol/L ± 59 micromol/L)
Study: 19957513
Drug: Non-cognitive impairment
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cognitive impairment group (serum uric acid level: 323 micromol/L ± 52 micromol/L)
Study: 15794407
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with Dermatophagoides pteronyssinus (500, 1000, 2000, 5000, 8000, and 10,000 biological units)
Study: 15794407
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with Dermatophagoides pteronyssinus
Study: 11142926
Drug: Willow bark
Normalized name: Willow bark
DrugBank: Willow bark (DB14691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Willow bark extract (240 mg salicin/day)
Study: 9835238
Drug: Treatments recommended
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments recommended by psychiatrists
Study: 2670536
Drug: ACC-9653 (phenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-9653 (phenytoin prodrug) intravenous administration
Study: 2670536
Drug: ACC-9653 (phenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-9653 (phenytoin prodrug) intramuscular administration
Study: 2670536
Drug: Sodium phenytoin
Normalized name: Phenytoin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium phenytoin intravenous administration
Study: 412590
Drug: 400 rads
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 rads of megavoltage irradiation to the site of the lesion given as a single dose and repeated 7 days later
Study: 30500603
Drug: Mipomersen 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 70 mg thrice weekly
Study: 30173291
Drug: Laparoscopic-assisted TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic-assisted TAP block with 30 ml 0.25% Bupivacaine
Study: 30173291
Drug: Periportal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periportal local anaesthetic infiltration with 15 ml of 0.5% Bupivacaine
Study: 27094918
Drug: Chiral bioanalytical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiral bioanalytical method for R‐ibuprofen and S‐ibuprofen
Study: 24612455
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg/day for at least 3 months (Group 1)
Study: 27118284
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group 2)
Study: 22275272
Drug: [phenyl‐U‐¹⁴C]‐aclidinium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: [phenyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Study: 22275272
Drug: [glycolyl‐U‐¹⁴C]‐aclidinium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: [glycolyl‐U‐¹⁴C]‐aclidinium bromide (400 µg, via 5 min infusion)
Study: 20370474
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) taken on awakening
Study: 20370474
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/day) taken at bedtime
Study: 30193001
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)/vitamin B6 (40 mg)
Study: 17645592
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg)/vitamin B12 (0.4 mg)
Study: 17645592
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 (40 mg) alone
Study: 16030154
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg levonorgestrel (LNG) daily, orally
Study: 16030154
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 0.5 mg dutasteride daily, orally
Study: 16030154
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 300 microg/kg acyline twice weekly, s.c.
Study: 16030154
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (TE; 100 mg, i.m., weekly) + 125 microg LNG daily, orally + 300 microg/kg acyline twice weekly, s.c.
Study: 12871685
Drug: L-NAME (1mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (1mg/Kg bolus and 1mg/Kg/h continuous IV drip for 5h)
Study: 10434810
Drug: Vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.2 mg kg‐1
Study: 6147155
Drug: Suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.5 mg kg‐1 (preceded by gallamine 20 mg 2 min earlier)
Study: 6147155
Drug: Vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg kg‐1 to 0.2 mg kg‐1
Study: 10566566
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin lispro plus sulfonylurea (L + S)
Study: 10566566
Drug: Bedtime neutral
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime neutral protamine Hagedorn (NPH) insulin plus sulfonylurea (N + S)
Study: 10566566
Drug: Preprandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preprandial insulin lispro plus bedtime NPH insulin (L + N)
Study: 8960576
Drug: Nitroglycerin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin administration
Study: 15646732
Drug: Metoprolol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol treatment
Study: 20031608
Drug: Verapamil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil treatment
Study: 29097388
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with thiazide diuretic and β-blocker
Study: 24560012
Drug: Paclitaxel, carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg)
Study: 10601174
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (CrS) - 6 x (5 g Cr‐H(2)O + 5 g dextrose)/day for 5 days
Study: 10601174
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 6 x 5 g dextrose/day for 5 days
Study: 8954023
Drug: MK-677 25
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-677 25 mg/day
Study: 1752455
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg four times a day for 8 to 16 weeks
Study: 1752455
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg twice a day
Study: 7042087
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy or BCG immunotherapy
Study: 31013455
Drug: Cannabis containing
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis containing THC (Cann‐CBD; 8 mg THC)
Study: 31013455
Drug: Cannabis containing
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD)
Study: 8672412
Drug: Soyabean-protein isolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soyabean-protein isolate (< 0.01 g phytic acid/kg)
Study: 1458074
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg repeated after 12 hours)
Study: 1424618
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg single dose)
Study: 27149586
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy exercise program (3 months)
Study: 16471090
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (40 mg/m² per week for six cycles)
Study: 16471090
Drug: Three-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-weekly cisplatin (75 mg/m² on days 1, 22, 43, and 64)
Study: 10669911
Drug: 1,000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/day of citicoline
Study: 8758141
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg base/kg over the first 3 days)
Study: 8758141
Drug: Tetracycline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline (4 mg/kg four times daily)
Study: 2435150
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy regimen (ABV/ADV) including doxorubicin, vinblastine, bleomycin/actinomycin D, vincristine, dacarbazine.
Study: 2435150
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (recombinant alpha interferon and ABV/ADV)
Study: 30354950
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg intravenous daily)
Study: 25611729
Drug: Standard ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard ribavirin dosing (group 1)
Study: 25611729
Drug: Low and
Normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low and escalating ribavirin dosing (group 2)
Study: 10443129
Drug: Topical levobunolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levobunolol
Study: 7719088
Drug: Kanggan Zhibao
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kanggan Zhibao (KGZB) oral liquor
Study: 5440736
Drug: 1·2 mega‐units
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1·2 mega‐units of aqueous procaine penicillin plus 1·0 g of probenecid given orally immediately prior to injection
Study: 26735225
Drug: Chloroquine 150
Normalized name: chloroquine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 150 mg once daily for 8 weeks
Study: 26735225
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 8 weeks
Study: 18071720
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and irinotecan with concurrent radiation (50.4 Gy)
Study: 18071720
Drug: Capecitabine, irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine, irinotecan and cetuximab with concurrent radiation (50.4 Gy)
Study: 10562782
Drug: melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin 5 mg
Study: 20523253
Drug: midazolam 15
Normalized name: midazolam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 15 mg
Study: 28494455
Drug: Testing for
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing for specific IgE antibodies against Bet v 6
Study: 26488737
Drug: Aloe vera-olive
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera-olive oil (AVO) cream
Study: 17263742
Drug: i.v. ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ketamine (0.5 mg/kg) (Group II)
Study: 17263742
Drug: peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: peritonsillar infiltration of ketamine (0.5 mg/kg) (Group III)
Study: 12189745
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg once daily for 52 weeks)
Study: 12189745
Drug: Tamsulosin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin + Serenoa repens (160 mg twice daily for 52 weeks)
Study: 2786422
Drug: Ketanserin (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (0.05, 1 or 2 mg kg‐1 h‐1)
Study: 2786422
Drug: Ketanserin (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (low and high doses)
Study: 2786422
Drug: Ketanserin (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (medium dose)
Study: 7208541
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg pivampicillin twice daily
Study: 7372355
Drug: 350 mg
Normalized name: hemin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg pivampicillin three times daily
Study: 17618948
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (Travasol 10% at 0.02 mL.kg(‐1).min(‐1))
Study: 17618948
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids (Travasol 10% at 0.02 mL.kg(‐1).min(‐1)) with glucose (4 mg.kg(‐1).min(‐1))
Study: 10202827
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg and saquinavir 400 mg twice daily
Study: 10202827
Drug: Ritonavir 600
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 600 mg and saquinavir 400 mg twice daily
Study: 10202827
Drug: Ritonavir 400
Normalized name: lopinavir-ritonavir 400 mg-100 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 400 mg and saquinavir 400 mg three times daily
Study: 10202827
Drug: Ritonavir 600
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir 600 mg and saquinavir 600 mg twice daily
Study: 10202827
Drug: Ritonavir‐saquinavir 600‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir‐saquinavir 600‐600 mg twice daily
Study: 8848902
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen 100 mg i.v. 2 min prior to induction of anaesthesia and an additional 100 mg infused in 60 min
Study: 10456820
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketoprofen
Study: 2286466
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol (3 g) single dose
Study: 2286466
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg twice daily for three days)
Study: 6779682
Drug: 24‐h continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24‐h continuous oxygen therapy
Study: 6779682
Drug: 12‐h nocturnal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12‐h nocturnal oxygen therapy
Study: 23652888
Drug: Daily shaving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily shaving with advanced products
Study: 23652888
Drug: Daily shaving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily shaving with standard products
Study: 21388554
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (3 times per week for 24 sessions over 8 weeks)
Study: 21388554
Drug: Waitlist group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist group (no acupuncture treatment for 8 weeks)
Study: 15519660
Drug: Alamifovir at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alamifovir at a total daily dose ranging from 2.5 to 20mg
Study: 11543734
Drug: Pindolol augmentation
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol augmentation
Study: 9209187
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe, 750 micrograms retinol, 250 micrograms folic acid, and 60 mg vitamin C per day
Study: 9209187
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Fe, 6000 micrograms retinol, 500 mg folic acid, and 60 mg vitamin C once a week
Study: 9209187
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg Fe and the same amount of the other three micronutrients as the second group once a week
Study: 3582475
Drug: Ranitidine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine alone (150 mg)
Study: 3582475
Drug: Ranitidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine with aluminum phosphate (11 g)
Study: 26361281
Drug: Time-delayed MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-delayed MRI with gadobenate dimeglumine (0.1-mmol/kg) administered immediately, followed by 2 axial T1-weighted sequences after 5-minute intervals (final image acquisition at 15 minutes).
Study: 26523330
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg triptorelin
Study: 11836309
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg leuprorelin
Study: 7577200
Drug: Short, pulse-intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short, pulse-intensive (single-dose) treatment regimens
Study: 23974823
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment regimens (implied control)
Study: 7151268
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg LT
Study: 7151268
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg LT
Study: 25179689
Drug: APF530 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF530 250 mg
Study: 19436223
Drug: CE cream
Normalized name: NAIR FACE CREAM,TOP
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE cream 0.3 mg daily for 12 weeks
Study: 19436223
Drug: CE cream
Normalized name: NAIR FACE CREAM,TOP
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE cream 0.3 mg twice weekly for 12 weeks
Study: 19436223
Drug: CE cream
Normalized name: NAIR FACE CREAM,TOP
DrugBank: Cholesteryl Linoleate (DB02092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE cream 0.3 mg daily and twice weekly
Study: 12846752
Drug: rhEPO in
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO in combination with intravenous iron
Study: 10714731
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of alendronate sodium
Study: 10714731
Drug: 60 or
Normalized name: QM-260 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 or 120 mg/d of raloxifene hydrochloride